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NeutrophiliaNeutrophil depleted mice are protected from concanavalin A-mediated hepatitis, showing that neutrophils are
critical for cellular liver damage. Interleukin-6 has pro- and anti-inﬂammatory properties and mediates
neutrophil recruitment in diseases such as rheumatoid arthritis. In classic signaling, interleukin-6 binds to the
membrane-bound interleukin-6-receptor and initiates signaling via gp130. In interleukin-6 trans-signaling, the
agonistic soluble interleukin-6-receptor can form a soluble interleukin-6/interleukin-6-receptor complex and
stimulate cells which only express gp130 but no interleukin-6-receptor. Interleukin-6 trans-signaling was
shown to be important for liver regeneration and development of liver adenomas. Here, we show that blocking
classic interleukin-6 signaling but not interleukin-6 trans-signaling reduced concanavalin A-induced liver
damage in mice, with reduced liver STAT3 phosphorylation and liver neutrophil accumulation. However, the
level of neutrophil-attracting chemokine KC is only reduced by inhibition of interleukin-6 trans-signaling.
Analysis of circulating neutrophils after concanavalin A challenge revealed that classic interleukin-6 signaling is
required for the mobilization of blood neutrophils. Reduced neutrophil inﬁltration was accompanied by
increased levels of hepatoprotective monocyte chemoattractant protein-1 and reduced level of hepatodestruc-
tive interleukin-4. Abrogated classic interleukin-6 signaling in concanavalin A-mediated hepatitis exhibited
liver-protective effects indicating that interleukin-6 classic but not interleukin-6 trans-signaling is responsible
for liver damage. Classic interleukin-6 signaling is required to mount an efﬁcient neutrophilia during
concanavalin A-induced immune response, which might have clinical implications in the regard that blocking
global interleukin-6 signaling pathways is a treatment option in different chronic inﬂammatory diseases.sche Forschungsgemeinschaft
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Hepatitis induced by the mitogenic plant lectin concanavalin A
(ConA) is amurinemodel of T cell-mediated liver injury and is driven by
up-regulation of cytokines including TNFα, IFNγ, IL-6, IL-12 and IL-4 [1].
The occurrence of hepatic lesions not only is characterized by CD4+ T
cell accumulation and to a lesser extent of CD8+ T cells but also involves
activation of resident hepatic NKT, Kupffer cells and neutrophils [2].Neutrophil depletion reduces liver damage indicating an essential role
for neutrophils in ConA-mediated hepatitis [3,4].
Interleukin-6 (IL-6) has pro- and anti-inﬂammatory functions [5]
and controls regenerative processes including wound healing and liver
regeneration [6,7]. IL-6 can induce signals via the membrane-bound
interleukin-6 receptor (IL-6R) and the signal transducing transmem-
brane receptor gp130 inaprocess called classic signalingand in complex
with the soluble IL-6R and gp130 in a process named trans-signaling [8].
Since the IL-6R is only sparely expressed, e.g. on hepatocytes and some
leucocyte subtypes, IL-6 trans-signaling dramatically increases the
number of potential IL-6 target cells [9]. Recent studies in animal
models of inﬂammatory bowel disease, peritonitis, rheumatoid arthritis,
acute inﬂammation and inﬂammatory colon cancer suggest that IL-6
trans-signaling rather than IL-6 classic signaling serves as themajor pro-
inﬂammatory paradigm under pathophysiological conditions [9]. A
soluble gp130 variant of the transmembrane receptor gp130 (sgp130)
speciﬁcally inhibits IL-6 trans-signaling leaving intact the classic
signaling [10]. In contrast, in IL-6 deﬁcient mice or in mice treated
with neutralizing anti-IL-6 or anti-IL-6Rmonoclonal antibodies (mAbs),
both classic IL-6 signaling and trans-signaling are blocked. Thereby,
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differentiate between classic and IL-6 trans-signaling.
IL-6 trans-signaling is important for liver regeneration and is
linked to development of liver adenomas [11,12]. Naturally, ligand-
independent constitutively active gp130 variants were described to
be responsible for inﬂammatory hepatocellular adenomas (IHACs)
[13] linking IL-6 to liver inﬂammation and regeneration.
In this study, we analyzed the role of classic IL-6-signaling and IL-6
trans-signaling on neutrophil inﬁltration during ConA-mediated
hepatitis using IL-6 deﬁcient mice and mice either injected with
anti-IL-6 mAb or sgp130Fc. We found that IL-6 deﬁcient mice and
mice treated with an anti-IL-6 mAb but not mice treated with an
sgp130Fc showed reduced ConA-induced liver injury. This was
accompanied by diminished increase of circulating blood and liver
inﬁltrating neutrophils, up-regulation of the hepatoprotective C-C
chemokine ligand 2 (CCL2)/monocyte chemoattractant protein-1
(MCP-1), down-regulation of the hepatodestructive cytokine IL-4
but unchanged levels of the neutrophil-attracting chemokine KC. Our
data show for the ﬁrst time that blockade of classic IL-6-signaling in
ConA-mediated hepatitis exhibited liver-protective effects, which
were in part caused by the failure to mount an efﬁcient neutrophilia
during ConA-induced immune response.
2. Material and methods
2.1. Mice and ConA treatment
Ten to twelve-week-old C57BL/6 wild-type and IL-6 knockout
mice with C57BL/6 background were obtained from Charles RiverA
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Fig. 1. IL-6 deﬁciency reduces ConA-mediated liver damage. Mice were treated with ConA (12
samples at the time points indicated. (A and B) IL-6 deﬁcient mice and control mice (n=5
treated with sgp130Fc and control mice (n=5). Values are shown as means±SD. *p≤0.05Laboratories (Sulzfeld, Germany) [14]. For all experiments, 3–8 male
mice per group were used. ConA (Type IV, Sigma, Deisenhofen,
Germany) dissolved in PBS was injected intravenously. All experi-
ments were performed according to the German guidelines for animal
care and protection (V 312-72241.121-3 (41-3/06)).
2.2. IL-6 antibody, sgp130Fc and hyper-IL-6 treatment, neutrophil
depletion
Male C57BL/6 mice were injected with 200 μg anti-IL-6 mAb
(clone: MP5-20F3, In Vivo BioTechServives, Henningsdorf, Germany)
or 250 μg sgp130Fc [10] i.p. 16 h prior to ConA or cytokine injection.
Mice were injected i.p. with 1 μg hyper-IL-6 [15] or 5 μg IL-6 and
sacriﬁced 90 min later. Neutrophils were depleted using 100 μg anti-
mouse Ly6G/Ly6C mAb (Clone: RB6-8C5, BD Bioscience, Heidelberg,
Germany) i.p. 18 h prior to ConA challenge. IL-6, hyper-IL-6 and
sgp130Fc were produced as previously described [10,15].
2.3. Serum alanine aminotransferase measurements
Serum alanine aminotransferase (ALT) and aspartate aminotrans-
ferase (AST) was determined using the ALT and AST detection kits
(Greiner Diagnostics, Bahlingen, Germany).
2.4. TNFα, IFNγ, KC, MCP-1 and IL-4 ELISA
Cytokine levels were measured via ELISA using DuoSet ELISA Kits
(R&D Systems, Wiesbaden, Germany). For IFNγ (Cat.No. DY485) and
TNFα (Cat.No. DY410), serumwas diluted 1:10 in 1% BSA/PBS. ForMCP-6000
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.5 μg/g). (A, C and E) ALT levels and (B, D and F) AST levels were determined from blood
). (C and D) Mice treated with anti-IL-6 mAb and control mice (n=5). (E and F) Mice
, **p≤0.01 and ***p≤0.001.
292 S. Malchow et al. / Biochimica et Biophysica Acta 1812 (2011) 290–3011 (Cat.No. DY479) andKC(Cat.No.DY453), serumwasdiluted 1:60 in 1%
BSA/PBS. For IL-4 (Cat.No. DY404), 5 μg/μl liver protein was used.
2.5. Western blotting
Livers were homogenized in lysis buffer (500 mM NaCl, 50 mM
Tris, pH 7.4, 0.1% SDS, 1% NP-40) containing complete proteaseFig. 2. IL-6 deﬁciency reduces ConA-mediated liver necrosis. Mice were treated with ConA
white arrows. (B, D and F) Quantiﬁcation of necrotic areas 48 h after ConA. Necrotic areas we
total area. (A and B) IL-6 deﬁcient mice and control mice (n=5). (C and D) Mice treated w
control mice (n=5). Values are shown as means±SD. *p≤0.05, **p≤0.01 and ***p≤0.001inhibitor cocktail (Roche, Mannheim, Germany). A 40 μg of total
protein was applied to SDS–PAGE gel electrophoresis and Western
blots were performed as described [16]. Primary antibodies were
diluted 1:1000 in blocking solution. The following antibodies were
used: β-actin, pSTAT3, STAT3 (Cell Signaling Technology, Frankfurt,
Germany) and horseradish-peroxidase coupled secondary antibodies
(Amersham Bioscience, Buckinghamshire, U.K.) at a dilution of(12.5 μg/g). (A, C and E) H&E stained sections 48 h after ConA. Necrosis is indicated by
re calculated from 30 random high-powered ﬁelds of three mice and given in percent of
ith anti-IL-6 mAb and control mice (n=5). (E and F) Mice treated with sgp130Fc and
, n.s., not signiﬁcant.
Fig. 3. Classic IL-6 signaling is responsible for STAT3 phosphorylation in the liver. Mice
(n=5) were treated with or without IL-6/hyper-IL-6 and with or without sgp130Fc for
90 min. pSTAT3 was analyzed by (A) Western blotting and (B) immunohistochemistry.
(C) Quantiﬁcation of STAT3 phosphorylation 1 h after treatment. STAT3 phosphoryla-
tion was calculated from 30 random high-powered ﬁelds of three mice.
293S. Malchow et al. / Biochimica et Biophysica Acta 1812 (2011) 290–3011:10,000. Signals were visualized using enhanced chemiluminescence
detection system (ECLplus Amersham Biosciences, Buckinghamshire,
U.K.). The membranes were exposed to the Image reader LAS-100 Pro
system (Fujiﬁlm, Düsseldorf, Germany).
2.6. Tissue processing and immunohistochemistry
Liver tissue was ﬁxed in 4% formalin, processed and immuno-
stained. Staining for neutrophils was carried out using a monoclonal
anti-mouse neutrophil mAb (AbDserotec, Düsseldorf, Germany)
diluted 1:2000 in sample diluent (Dako, Glostrup, Denmark). After
incubation with anti-rat antibodies (Dako, Glostrup, Denmark) and
EnVision-HRP (Dako, Glostrup, Denmark), the signal was developed
with AEC Substrate (Dako, Glostrup, Denmark) and samples were
counterstained with Shandon Gill3 Hematoxylin (Thermo Scientiﬁc,
Cheshire, UK). Staining for STAT3 phosphorylation was carried out
using anti-pSTAT3 mAb (Cell signaling, Danvers, MA) diluted 1:3000
and the signal was ampliﬁed using the Tyramide Signal Ampliﬁcation
kit (Perkin Elmer, Boston, MA), developed as described before,
differentiated in 0.5% acetic acid, rinsed in tap water and stained
with Giemsa's azur eosin methylene blue solution (Merck, Darmstadt,
Germany). Liver damage was quantiﬁed using ImageJ-Software.
2.7. Flow cytometry analysis
A 25 μl whole blood was supplemented with 100 μl EDTA-buffer
(2 mM EDTA, 0.2% BSA in PBS). Samples were blocked with 0.5 μl rat-
serum (Jackson ImmunoResearch, Suffolk, England) and 0.5 μl anti-
mouse Fc block (BD Bioscience, Heidelberg, Germany). Cells were
stained with PE-conjugated anti-CD11b (BD Bioscience, Heidelberg,
Germany), APC-conjugated anti-CD3e (BD Bioscience) and FITC-
conjugated anti-Ly6G/Ly6C (BD Bioscience). Erythrocytes were lysed
and cells were ﬁxed with the FACS lysing solution (BD Bioscience).
Cells were suspended in FACS buffer (PBS/0.2% BSA) and analyzed
using FACSCanto and DIVA software (BD).
Livers were pressed through a nylon mash (BD Bioscience, 40 μm
cell strainer). Cell suspension was centrifuged at 300g for 5 min.
Erythrocytes were lysed in lysing solution (150 mM NH4Cl, 10 mM
KHCO3, 100 nM EDTA). A 2 ml cell suspension in RPMI-1640 medium
was overlaid onto 2.5 ml Histopaque (Sigma, Deisenhofen, Germany)
and centrifuged for 30 min at 300g. MNCs were washed in 10 ml 5%
FCS/PBS and resuspended in 50 μl 5% FCS/PBS. Cells were stained with
APC-anti-CD3e mAb (BD Bioscience), FITC–anti-CD4 mAB
(eBioscience) and PE–Cy7-anti-CD69 mAb (BD Bioscience).
2.8. Statistical analysis
All results are expressed as arithmetic mean±SD. An unpaired
Student's t test was used for comparisons between 2means. Statistical
signiﬁcance was set at *p≤0.05, **p≤0.01 and ***p≤0.001.
3. Results
3.1. Abrogation of classic IL-6 signaling but not IL-6 trans-signaling
reduces ConA-mediated liver hepatitis
Intravenous administration of a single dose of ConA (12.5 μg/g)
resulted in lower plasma alanine transaminase (ALT) and aspartate
aminotransferase (AST) serum levels in male IL-6 deﬁcient C57BL/6
mice compared to male C57BL/6 control mice 8 h after treatment and
comparable levels after 24 and 48 h in IL-6 deﬁcient compared to
control mice (Fig. 1A and B). Histological examination of the overall
liver damage 48 h after ConA administration showed smaller necrotic
areas in IL-6 deﬁcient mice compared to control mice (Fig. 1C and D).
Quantiﬁcation of liver damage 48 h after ConA-induced hepatitis
indicated that only 14.5% of the liver was necrotic in IL-6 deﬁcientmice compared to 47% in control mice (Fig. 2A and B). This indicates
that over time less ALT/AST is released, which in sum reﬂects overall
reduction of liver damage in IL-6 deﬁcient mice.
Liver damage in mice, which received a single injection of
neutralizing anti-IL-6 mAbs 16 h before ConA, was reminiscent to
the one seen in IL-6 deﬁcient mice (Figs. 1C, 1D and 2E).
Quantiﬁcation indicated that only 9.6% of the liver was necrotic in
anti-IL-6 mAb pre-treated mice compared to 39% in control mice
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inhibitor sgp130Fc 16 h before ConA was identical to control mice
(Figs. 1E, 1F and 2E). Quantiﬁcation indicated that 33.2% of the liver
was necrotic in sgp130Fc pre-treated mice compared to 36.4% in
control mice (Fig. 2F). Here, we used a standard sgp130Fc dose,
proven to be sufﬁcient to block systemic and local IL-6 trans-signalingFig. 4. IL-6, sIL-6R serum level and liver STAT3 phosphorylation during ConA-mediated hepa
determined by ELISA. Values are shown as means±SD. Control mice, IL-6 deﬁcient mice, mic
2 h (C), 4 h (D) and (E) 8 h. pSTAT3 was analyzed by Western blotting.in mice [16,19]. Soluble gp130Fc is a fusion protein of the extracellular
domains of the transmembrane receptor gp130 fused to the Fc-part of
an IgG antibody, facilitating dimerization of sgp130Fc. Importantly,
sgp130Fc speciﬁcally inhibits IL-6 trans-signaling but not IL-6 classic
signaling, whereas in IL-6 deﬁcient mice and anti-IL-6 treated mice,
both IL-6 classic signaling and IL-6 trans-signaling were blocked [10].titis. Control mice received ConA (12.5 μg/g, n=5). (A) Serum IL-6 and (B) sIL-6R were
e treated with anti-IL-6 mAb or sgp130Fc (n=5)were treated with ConA (12.5 μg/g) for
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signaling plays a major role in ConA-mediated liver damage.
3.2. Classic IL-6 signaling mediates STAT3 phosphorylation in
ConA-mediated hepatitis
Whereas gp130 is ubiquitously expressed, expression of the IL-6R
is limited to cell populations such as lymphocytes and hepatocytes.
However, it has been shown that despite the low expression of IL-6RFig. 5. STAT3 phosphorylation in the liver during ConA-mediated hepatitis. pSTAT3 was an
anti-IL-6 mAb or sgp130Fc (n=5) were treated with ConA (12.5 μg/g) for 2 h (A), 4 h (B)
Quantiﬁcation of STAT3 phosphorylation 2, 4 and 8 h after ConA injection. STAT3 phosphorin hepatocytes, IL-6 trans-signaling is a vital mechanism to induce
hepatocyte activation under stress condition such as D-Gal induced
liver damage [7,20]. Therefore, we analyzed whether sustained IL-6-
signaling in the liver can bemediated by IL-6 classic signaling. IL-6 and
hyper-IL-6 (H-IL-6) with or without sgp130Fc were injected i.p. and
liver tissue was analyzed for STAT3 phosphorylation (pSTAT3).
Hyper-IL-6 is a fusion protein consisting of IL-6 fused to the sIL-6R
by a ﬂexible peptide linker speciﬁcally mimicking IL-6 trans-signaling
[15]. As expected, both IL-6 and hyper-IL-6 induced pSTAT3 in thealyzed by immunohistochemistry. Control mice, IL-6 deﬁcient mice, mice treated with
and 8 h (C). pSTAT3 positive cells (in pink/red) are indicated by black arrows. (D–F)
ylation was calculated from 30 random high-powered ﬁelds of three mice.
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showed that 188 and 181 cells/HPF in IL-6 and hyper-IL-6 injected
animals were positive for STAT3 phosphorylation, respectively
(Fig. 3C), whereas only 2 cells/HPF were positive in control mice.
pSTAT3 induced by hyper-IL-6 but not by IL-6 was inhibited by
sgp130Fc as detected byWestern blotting and immunohistochemistry
of liver sections (Fig. 3A and B). Quantiﬁcation of immunohistochem-
ical data showed that 185 and 18 cells/HPF in IL-6/sgp130Fc and
hyper-IL-6/sgp130Fc injected animals were positive for STAT3
phosphorylation, respectively (Fig. 3C).
Next we analyzed IL-6 and sIL-6R levels in ConA-injected wild-
typemice. IL-6 is induced immediately after ConA injection and barely
detectable after 24 and 48 h (Fig. 4A). However, serum level of sIL-6R
of about 10 ng/ml exceeded that of IL-6 and was also slightly
increased during ConA-mediated hepatitis and high enough to allow
IL-6 trans-signaling (Fig. 4B). STAT3 phosphorylation induced by IL-6
can be detected as early as 2 h after ConA injection and is still at the
8 h time point. In comparison to control mice, 2, 4 and 8 h after ConA
challenge reduced pSTAT3 was detected in IL-6 deﬁcient mice and
anti-IL-6mAb treatedmice but not in sgp130Fc treatedmice as shown
byWestern blotting and immunhistochemistry (Figs. 4C–E and 5A–C).
Quantiﬁcation of immunohistochemical data showed that at 2, 4 and
8 h time points in IL-6-deﬁcient, anti-IL-6 treated animals but not in
sgp130Fc treated animals STAT3 phosphorylation was signiﬁcantly
reduced in comparison to control mice (Fig. 5D–F). These results
showed that during ConA-mediated hepatitis the liver is a target ofFig. 6. IL-6 deﬁciency is accompanied by reduced numbers of liver neutrophils during ConA-m
mAb or sgp130Fc (n=5) were treated with ConA (12.5 μg/g). (A and C) Immunostained ne
ConA treatment. Representative liver slides immunostained for neutrophils (black arrows),
**p≤0.01 and ***p≤0.001.classic IL-6 signaling and not of IL-6 trans-signaling, although the liver
clearly has the potential to conduct IL-6 trans-signaling [11,21].
3.3. IL-6 deﬁciency is accompanied by reduced numbers of liver
neutrophils during ConA-mediated hepatitis
IL-6 deﬁcient mice failed to recruit neutrophils to the kidney
during acute kidney injury. Both IL-6 deﬁcient or neutrophil depleted
micewere found to be protected from acute kidney injury [22]. Failure
of neutrophil transmigration in IL-6 deﬁcient mice was also shown for
artery occlusion shock [23]. Neutrophils play an essential role in
ConA-mediated hepatitis [4,5]. IL-6 deﬁcient mice and mice treated
with anti-IL-6 mAb showed 1.8 fold reduction of liver neutrophils
whereas mice treated with sgp130Fc had no reduction of liver
neutrophils compared to control mice (Fig. 6A and B). Neutrophils
were speciﬁcally localized at the border areas of liver damage. At the
48 h time point, we detected reduced neutrophil accumulation in IL-6
deﬁcient mice but not in anti-IL-6 mAb and sgp130Fc treated animals
compared to control mice (Fig. 6C and D). This might indicate that the
single injection of anti-IL-6 mAb suppressed IL-6 signaling to a lower
extent as in IL-6 deﬁcient mice. This is also reﬂected by the analysis of
phosphor-STAT3 level in IL-6 deﬁcient and anti-IL-6 mAb treated
mice. We concluded that neutrophil recruitment by classic IL-6
signaling is disturbed in IL-6 deﬁcient and anti-IL-6 mAb treated mice
but not by IL-6 trans-signaling in sgp130Fc treated mice after ConA
challenge.ediated hepatitis. Control mice (n=3), IL-6 deﬁcient mice, mice treated with anti-IL-6
utrophils were counted from 10 random high-powered ﬁelds (n=3) 8 and 48 h after
8 h (B) and 48 h (D) after ConA treatment. Data are the means±SD (n=5). *p≤0.05,
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pre-activated CD4+/CD69+ T cells before ConA stimulation (38% vs.
25%). At the moment, we cannot explain the differences in pre-
activated T cells before ConA stimulation. However, after ConA
injection, the percentages of CD3+/CD4+ T cells from total liver-
lymphocytes and liver activated CD4+/CD69+ T cells in IL-6 deﬁcient
compared to control mice were reduced, suggesting a role of IL-6 on
activation of CD4+ T cells (Fig. 7A and B).A B
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decreased hepatodestructive IL-4 during ConA-mediated hepatitis
As previously reported [4], neutrophil depletion protected mice
from ConA-mediated hepatitis (Supplementary Fig. 1). Using C57BL/6
mice, liver-accumulated neutrophils inhibited the production of MCP-
1 by Kupffer cells during Listeria monocytogenes infection [24]. MCP-1
confers protective effects in ConA-mediated liver injury in C57BL/6
mice [25]. Neutralization of MCP-1 led to an increase in liver damage
and increased IL-4 secretion from activated liver-resident NKT cells
which exhibit pro-inﬂammatory effects in ConA-treated C57BL/6mice
[25,26]. Neutrophil depleted mice showed higher MCP-1 levels as
compared to control mice during ConA-mediated hepatitis (Fig. 8A).
Levels of the neutrophil-attracting chemokine KC were unaffected
(Fig. 8B) but IL-4 level were reduced (Fig. 8C). These data might
indicate a connection between neutrophil inﬁltration and MCP-1
expression during ConA-mediated hepatitis.
MCP-1 levels were also signiﬁcantly elevated in IL-6 deﬁcient
mice and mice treated with an anti-IL-6 mAb but not with sgp130Fc
8 h after ConA-induced hepatitis compared to control mice (Fig. 8A).A
10
12.5
***
IL-6 -/-
control
7.5
10
Ly6G/Ly6C
control
**
B
8 24 48
0
2.5
50
7.5
8 24 48
0
2.5
5
time aft
M
CP
-1
 [n
g/m
l]
10
15
20
25
30 IL-6-/-
control
20
30
40
50
60
70
K
C 
[n
g/m
l]
Ly6G/Ly6C
control
C
8 24 48
0
5
8 24 48
0
10
time aft
14
16
*
D 12
0
2
4
6
8
10
12
liv
er
 IL
-4
 [p
g/m
g]
8h
 a
fte
r C
on
A
0
2
4
6
8
10
liv
er
 IL
-4
 [p
g/m
g]
 
8h
 a
fte
r C
on
A
Ly6G/Ly6C control IL-6-/- anti-IL-6
mAb
Fig. 8. IL-6 classic and trans-signaling inﬂuence the inﬂammatory cytokine and chemokine l
anti-Ly6G/Ly6C mAb (100 μg/mouse), anti-IL-6 mAb (200 μg/mouse) or sgp130Fc (250 μg/m
by ELISA. (C and D) Liver IL-4 was determined by ELISA 8 h after ConA injection. Values areEven though abrogated classic IL-6 signaling led to diminished
neutrophils in the liver, the neutrophil-attracting chemokine KC was
not changed in IL-6 deﬁcient mice and anti-IL-6 mAb treated mice.
However, we observed a signiﬁcant reduction of KC level after IL-6
trans-signaling inhibition, which has no inﬂuence on neutrophil
migration into the liver (Fig. 8B). Since MCP-1 suppressed IL-4
expression in NKT cells in vitro [25] and reduced IL-4 level were
found in neutrophil depleted mice during ConA-mediated hepatitis
[5], we analyzed IL-4 levels in liver samples. We found a reduction of
IL-4 in IL-6 deﬁcient and in anti-IL-6 mAb but not in sgp130Fc
treated mice 8 h after ConA injection as compared to control mice
indicating that classic IL-6 signaling positively regulated IL-4
production (Fig. 8D).
3.5. Deﬁciency of classic IL-6 signaling caused reduced level of circulating
neutrophils in the peripheral blood during ConA-mediated hepatitis
Intravenous injection of IL-6 has been described to induce
neutrophilia with an early phase caused by mobilization of
neutrophils into the peripheral blood from the marginated pool of7.5
9 anti-IL-6 mAb
control
***
5
6 sgp130Fc
control
8 24 48
0
1.5
3
4.5
6
8 24 48
0
1
2
3
4
er ConA [h]
5
10
15
20
anti-IL-6 mAb
control
8
12
16
20
sgp130Fc
control
*
8 24 48
0
8 24 48
0
4
er ConA [h]
*
*
sgp130Fc control
evels in ConA challenged mice. Control mice, IL-6 deﬁcient mice and mice treated with
ouse) received ConA (12.5 μg/g, n=5). (A) Serum MCP-1 and (B) KC were determined
shown as means±SD. *p≤0.05, **p≤0.01 and ***p≤0.001.
A
20
5
10
15
anti-IL-6mAb
sgp130Fc
control*
*
*
B
0
IL-6 +  +   +  -
Ly
6G
/L
y6
Ch
ig
h /C
D1
1b
hi
gh
 
[%
]
Ly
6G
/L
y6
Ch
ig
h /C
D1
1b
hi
gh
 
[%
]
10
20
30
40
50 IL-6-/-
anti-IL-6 mAb
control
*
*
**
**
*** sgp130Fc
0
ConA - + ++ - +
Fig. 9. Deﬁciency of classic IL-6 signaling caused reduced level of circulating neutrophils
in the peripheral blood during ConA-mediated hepatitis. (A) 200 μg/mouse anti-IL-6
mAb or 250 μg/mouse sgp130Fc were injected i.p. in mice (n=4). Sixteen hours after
the ﬁrst injection, mice received i.v. injection of 2 μg/mouse IL-6. Neutrophils in
peripheral blood were determined by ﬂow cytometry using anti-Ly6G and anti-CD11b
mAbs, 4 h after IL-6 injection. (B) Control mice, IL-6 deﬁcient mice and mice treated
with anti-IL-6 mAb or sgp130Fc received ConA (12.5 μg/g, n=5). Neutrophils in
peripheral blood were determined 8 h after ConA injection as described before. Values
are shown as means±SD. *p≤0.05, **p≤0.01 and ***p≤0.001.
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accelerated bone marrow release of neutrophils [27,28]. Here, we
provide evidence that neutrophilia is mediated by classic IL-6
signaling but not by IL-6 trans-signaling. IL-6 with or without anti-
IL-6 mAb or sgp130Fc was injected i.v. and levels of circulating
neutrophils in the peripheral blood were analyzed after 4 h. IL-6
treatment induced a strong neutrophil response, which could be
speciﬁcally inhibited with anti-IL-6 mAb but not with sgp130Fc
(Fig. 9A).
Reduced levels of circulating neutrophils in the peripheral blood
were observed in IL-6 deﬁcient mice during Listeria monocytogenes
infection [29], indicating that endogenously produced IL-6 is required
to mount an efﬁcient neutrophilia. A 5.4 fold increase of circulating
neutrophils in the peripheral blood was observed 8 h after ConA
administration, which was reduced in IL-6 deﬁcient mice (2.4 fold)
and mice treated with anti-IL-6 mAb (3.2 fold) but not with sgp130Fc
(Fig. 9B).
4. Discussion
Activation of T cells is a critical process in the pathophysiology of
human autoimmune liver diseases and viral hepatitis. T cell-mediated
hepatitis in mice can be mimicked with injection of ConA and tissue
injury is limited to the liver. When treated with ConA, mice develop
an acute, partly apoptotic hepatic injury that develops into massive
necrosis. Although CD4+ T cells are key players in this model, several
cell depletion studies showed that other cell types including NKT cells,
Kupffer cells and neutrophils are also required to induce full-blown
ConA-mediated hepatitis [3]. Immunoregulatory cytokines play acentral role in the pathogenesis of ConA-mediated hepatitis with
studies pointing to a pro-inﬂammatory role of TNFα, IFNγ, IL-12 and
IL-4 and a protective role of IL-10 and MCP-1 [1].
IL-6 was described to be hepatoprotective when injected before
ConA but hepatodestructive when injected after ConA [17,30–33].
Studies with IL-6 deﬁcient mice revealed a hepatoprotective role of IL-
6 [17,18], which is opposite to the ﬁndings in our study. However, it
has been widely neglected that IL-6 deﬁcient mice have been found to
release less ALT during the early phase, which we have also observed
[17]. Our study and the earlier studies only differ in later time points
after ConA administration, where IL-6 deﬁcient mice exhibited higher
ALT level, which we failed to reproduce [17,18]. In all experiments, we
used genetically identical mice (C57BL6), same sex and same age. We
independently reproduced our ﬁndings using mice treated with
neutralizing anti-IL-6 mAbs 16 h before ConA application.
Protection was not mediated by IL-6 trans-signaling since mice
treated with the IL-6 trans-signaling inhibitor sgp130Fc showed liver
damage comparable to control mice. Even though liver cells including
hepatocytes and Kupffer cells express IL-6R and are therefore a likely
target of classic IL-6 signaling, the liver is also a target of IL-6 trans-
signaling, which enhanced stimulatory effects of IL-6 [34]. Since
hepatocytes express far more gp130 than IL-6R on the cell surface, the
total number of activated gp130 molecules is higher when IL-6 plus
sIL-6R are present [35]. Abrogation of classic IL-6 signaling reduced
pSTAT3 in ConA-mediated hepatitis, indicating that IL-6 on liver cells
acts via the membrane-bound IL-6R and not the sIL-6R. This was
further supported by direct injection of IL-6 and the trans-signaling-
inducing designer cytokine hyper-IL-6. Here, sgp130Fc speciﬁcally
inhibited only the hyper-IL-6 but not the IL-6 induced pSTAT3. Mice
transgenic for IL-6 and the soluble IL-6R had higher liver weight and
showed extramedullary hematopoiesis in liver and spleen and
developed multifocal hepatocellular hyperplasia [20,36]. IL-6 levels
have been shown to be strongly increased during chemical liver
damage induced by substances such as D-galactosamine [37].
Blockade of IL-6 trans-signaling by sgp130Fc showed that liver
regeneration and regulation of glycogen consumption in the D-Gal
liver toxicity model is mediated by IL-6 trans-signaling [7]. These data
showed that IL-6 trans-signaling processes in the liver are possible
despite expression of membrane-bound IL-6R on liver cells including
hepatocytes.
TNFα and IFNγ were not changed between IL-6 deﬁcient and
control mice, whereas defective classic IL-6 signaling leads to lower
accumulation of neutrophils in the liver and subsequent up-
regulation of MCP-1 and down-regulation of IL-4. This is in line with
data showing that neutrophil depleted animals were protected from
ConA-mediated hepatitis with higher MCP-1 and lower IL-4 level
[4,5]. In a Listeria monocytogenes infection model, phagocytosis of
neutrophils by Kupffer cells led to inhibition of MCP-1 by Kupffer cells
[24]. The protective effect of MCP-1 in ConA-mediated hepatitis was
demonstrated since neutralization of MCP-1 led to an increase in liver
damage and increased hepatodestructive IL-4 secretion from activat-
ed liver-resident NKT cells [25]. Recombinant MCP-1 was able to
reduce IL-4 production in vitro by ConA-costimulated NKT cells [25].
We conclude that this sequence of events might also apply for ConA-
mediated hepatitis.
Lafdil et al. [38] demonstrates decreased ConA hepatotoxicity and
neutrophil inﬁltration in mice with STAT3-deﬁciency in T cells but
more hepatotoxicity in mice with STAT3 deletion in myeloid cells
(Macrophages, Dendritic Cells and Neutrophils), which suggests
differential effects of IL-6 signaling reﬂecting the dynamic crosstalk
of inﬂammatory cell types in ConA-mediated hepatitis. Even though
we observed reduced neutrophil percentages in the liver in ConA-
treated IL-6 deﬁcient mice with abrogated classic IL-6 signaling,
level of the neutrophil-attracting chemokine KC were unchanged,
which indicated that neutrophil recruitment processes into the liver
might not be directly affected by IL-6 blockade. Analysis of IL-6
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hepatitis IL-6 classic signaling is responsible for mounting a
sufﬁcient/efﬁcient neutrophilia, indicating that the destructive
ConA-effect of IL-6 is not restricted to the liver. In line, IL-6 was
shown to be important for neutrophilia during Listeria monocyto-
genes infection [29]. This mechanism appears to be independent of
production and differentiation of granulocytes, which is governed on
both granulocyte colony-stimulating factor (G-CSF) and granulo-
cyte–macrophage colony-stimulating factor (GM-CSF) and after
exposure to pathogens on an alternative pathway facilitated by IL-
6 trans-signaling [39].
The failure to mount an efﬁcient neutrophilia after ConA-mediated
hepatitis caused by blockade of global IL-6 signaling with a
neutralizing anti-IL-6 antibody might have clinical implications. Our
data have to be taken into account in the regard that blocking global
IL-6 signaling pathways with the anti-IL-6R mAb Tocilizumab is a
treatment option in different chronic inﬂammatory diseases. We
clearly show that consequences of a blockade of classic IL-6 signaling
pathway but not of IL-6 trans-signaling inhibit neutrophil recruit-
ment. There are at least two possible opposite scenarios, which should
be analyzed in future work. Firstly, inhibition of neutrophilia may be
part of the proven beneﬁcial effects of anti-IL-6 and anti-IL-6R
antibodies in the treatment of rheumatoid arthritis as neutrophils
play a role in propagation of joint inﬂammation. Secondly, neutro-
philia may be part of the negative side effects of these therapies since
neutrophils are also important mediators of innate immunity to
defend infections. Therefore, it might be an attractive option to use the
IL-6 trans-signaling inhibitor sgp130Fc as a future therapy in chronic
diseases such as Rheumatoid arthritis and Crohn's disease.
Supplementarymaterials related to this article can be found online
at doi: 10.1016/j.bbadis.2010.11.009.
Acknowledgments
The authors thank Stefanie Schnell for the technical assistance and
Claudia Drucker for the helpful discussion.
References
[1] G. Tiegs, Cellular and cytokine-mediated mechanisms of inﬂammation and its
modulation in immune-mediated liver injury, Z. Gastroenterol. 45 (2007)
63–70.
[2] Z. Dong, H.Wei, R. Sun, Z. Tian, The roles of innate immune cells in liver injury and
regeneration, Cell. Mol. Immunol. 4 (2007) 241–252.
[3] C.S. Bonder, M.N. Ajuebor, L.D. Zbytnuik, P. Kubes, M.G. Swain, Essential role for
neutrophil recruitment to the liver in concanavalin A-induced hepatitis, J.
Immunol. 172 (2004) 45–53.
[4] S. Hatada, T. Ohta, Y. Shiratsuchi, M. Hatano, Y. Kobayashi, A novel accessory role
of neutrophils in concanavalin A-induced hepatitis, Cell. Immunol. 233 (2005)
23–29.
[5] T. Kishimoto, S. Akira, M. Narazaki, T. Taga, Interleukin-6 family of cytokines and
gp130, Blood 86 (1995) 1243–1254.
[6] C. Drucker, B. Rabe, A. Chalaris, E. Schulz, J. Scheller, S. Rose-John, Interleukin-6
trans-signaling regulates glycogen consumption after D-galactosamine-induced
liver damage, J. Interferon Cytokine Res. 29 (2009) 711–717.
[7] C. Drucker, J. Gewiese, S. Malchow, J. Scheller, S. Rose-John, Impact of interleukin-
6 classic- and trans-signaling on liver damage and regeneration, J. Autoimmun. 34
(2010) 29–37.
[8] S. Rose-John, P.C. Heinrich, Soluble receptors for cytokines and growth factors:
generation and biological function, Biochem. J. 300 (1994) 281–290.
[9] S. Rose-John, J. Scheller, G. Elson, S. Jones, Interleukin-6 biology is coordinated by
membrane-bound and soluble receptors: role in inﬂammation and cancer, J Leuk
Biol 80 (2006) 227–236.
[10] T. Jostock, J. Müllberg, S. Özbek, R. Atreya, G. Blinn, N. Voltz, M. Fischer, M.F.
Neurath, S. Rose-John, Soluble gp130 is the natural inhibitor of soluble IL-6R
transsignaling responses, Eur. J. Biochem. 268 (2001) 160–167.
[11] M. Peters, P. Schirmacher, J. Goldschmitt, M. Odenthal, C. Peschel, H.P. Dienes, E.
Fattori, G. Ciliberto, K.H. Meyer Test, Extramedullary expansion of hematopoietic
progenitor cells in IL-6/sIL-6R double transgenic mice, J. Exp. Med. 185 (1997)
755–766.
[12] D. Maione, E. Di Carlo, W. Li, P. Musiani, A. Modesti, M. Peters, S. Rose-John, C.
Della Rocca, M. Tripodi, D. Lazzaro, R. Taub, R. Savino, G. Ciliberto, Coexpression of
IL-6 and soluble IL-6R causes nodular regenerative hyperplasia and adenomas of
the liver, EMBO J. 17 (1998) 5588–5597.[13] S. Rebouissou, M. Amessou, G. Couchy, K. Poussin, S. Imbeaud, C. Pilati, T.
Izard, C. Balabaud, P. Bioulac-Sage, J. Zucman-Rossi, Frequent in-frame
somatic deletions activate gp130 in inﬂammatory hepatocellular tumours,
Nature 457 (2009) 200.
[14] M. Kopf, H. Baumann, G. Freer, M. Freudenberg, M. Lamers, T. Kishimoto,
R. Zinkernagel, H. Bluethmann, G. Kohler, Impaired immune and acute-
phase responses in interleukin-6-deﬁcient mice, Nature 368 (1994)
339–342.
[15] M. Fischer, J. Goldschmitt, C. Peschel, J.P. Brakenhoff, K.J. Kallen, A. Wollmer, J.
Grotzinger, S. Rose-John, A bioactive designer cytokine for human hematopoietic
progenitor cell expansion, Nat. Biotechnol. 15 (1997) 145-145.
[16] B. Rabe, A. Chalaris, U. May, G.H. Waetzig, D. Seegert, A.S. Williams, S.A. Jones, S.
Rose-John, J. Scheller, Transgenic blockade of interleukin 6 transsignaling
abrogates inﬂammation, Blood 111 (2008) 1021–1028.
[17] F. Hong, B. Jaruga, W.H. Kim, S. Radaeva, O.N. El-Assal, Z. Tian, V.A. Nguyen, B. Gao,
Opposing roles of STAT1 and STAT3 in T cell-mediated hepatitis: regulation by
SOCS, J. Clin. Invest. 110 (2002) 1503–1513.
[18] Y. Tagawa, P. Matthys, H. Heremans, C. Dillen, Z. Zaman, Y. Iwakura, A. Billiau,
Bimodal role of endogenous interleukin-6 in concanavalin A-induced hepatitis in
mice, J. Leukoc. Biol. 67 (2000) 90–96.
[19] R. Atreya, J. Mudter, S. Finotto, J. Müllberg, T. Jostock, S. Wirtz, M. Schütz, B.
Bartsch, M. Holtmann, C. Becker, D. Strand, J. Czaja, J.F. Schlaak, H.A. Lehr, F.
Autschbach, G. Schürmann, N. Nishimoto, K. Yoshizaki, H. Ito, T. Kishimoto, P.R.
Galle, S. Rose-John, M.F. Neurath, Blockade of IL-6 transsignaling abrogates
established experimental colitis in mice by suppression of the antiapoptotic
resistance of lamina propria T cells, Nat. Med. 6 (2000) 583–588.
[20] M. Peters, P. Schirmacher, J. Goldschmitt, M. Odenthal, C. Peschel, E. Fattori, G.
Ciliberto, H.P. Dienes, K.H. Meyer zum Büschenfelde, S. Rose-John, Extramedullary
expansion of hematopoietic progenitor cells in interleukin (IL)-6–sIL-6R double
transgenic mice, J. Exp. Med. 185 (1997) 755–766.
[21] C. Drucker, B. Rabe, A. Chalaris, E. Schulz, J. Scheller, S. Rose-John, Interleukin-6
trans-signaling regulates glycogen consumption after D-galactosamine-induced
liver damage, J. Interferon Cytokine Res. (2009)8 [Epub ahead of print].
[22] Y. Nechemia-Arbely, D. Barkan, G. Pizov, A. Shriki, S. Rose-John, E. Galun, J.H.
Axelrod, IL-6/IL-6R axis plays a critical role in acute kidney injury, J. Am. Soc.
Nephrol. 19 (2008) 1106–1115.
[23] S. Cuzzocrea, G. De Sarro, G. Costantino, G. Ciliberto, E. Mazzon, A. De Sarro, A.P.
Caputi, IL-6 knock-out mice exhibit resistance to splanchnic artery occlusion
shock, J. Leukoc. Biol. 66 (1999) 471–480.
[24] M. Holub, C.W. Cheng, S. Mott, P. Wintermeyer, N. van Rooijen, S.H. Gregory,
Neutrophils sequestered in the liver suppress the proinﬂammatory response
of Kupffer cells to systemic bacterial infection, J. Immunol. 183 (2009)
3309–3316.
[25] M.N. Ajuebor, C.M. Hogaboam, T. Le, M.G. Swain, C-C chemokine ligand 2/
monocyte chemoattractant protein-1 directly inhibits NKT cell IL-4 production
and is hepatoprotective in T cell-mediated hepatitis in the mouse, J. Immunol. 170
(2003) 5252–5259.
[26] Y. Kaneko, M. Harada, T. Kawano, M. Yamashita, Y. Shibata, F. Gejyo, T. Nakayama,
M. Taniguchi, Augmentation of Valpha14 NKT cell-mediated cytotoxicity by
interleukin 4 in an autocrine mechanism resulting in the development of
concanavalin A-induced hepatitis, J. Exp. Med. 191 (2000) 105–114.
[27] T.R. Ulich, J. del Castillo, K.Z. Guom, In vivo hematologic effects of recombinant
interleukin-6 on hematopoiesis and circulating numbers of RBCs andWBCs, Blood
73 (1989) 108–110.
[28] T. Suwa, J.C. Hogg, D. English, S.F. Van Eeden, Interleukin-6 induces demargination
of intravascular neutrophils and shortens their transit in marrow, Am. J. Physiol.
Heart Circ. Physiol. 279 (2000) 1613–1617.
[29] S.A. Dalrymple, L.A. Lucian, R. Slattery, T. McNeil, D.M. Aud, S. Fuchino, F. Lee, R.
Murray, Interleukin-6-deﬁcient mice are highly susceptible to Listeria mono-
cytogenes infection: correlation with inefﬁcient neutrophilia, Infect. Immun. 63
(1995) 2262–2268.
[30] H. Mizuhara, E. O'Neill, N. Seki, T. Ogawa, C. Kusunoki, K. Otsuka, S. Satoh, M. Niwa,
H. Senoh, H. Fujiwara, T cell activation-associated hepatic injury: mediation by
tumor necrosis factors and protection by interleukin 6, J. Exp. Med. 179 (1994)
1529–1537.
[31] H. Mizuhara, M. Uno, N. Seki, M. Yamashita, M. Yamaoka, T. Ogawa, K. Kaneda, T.
Fujii, H. Senoh, H. Fujiwara, Critical involvement of interferon gamma in the
pathogenesis of T-cell activation-associated hepatitis and regulatory mechanisms
of interleukin-6 for the manifestations of hepatitis, Hepatology 23 (1996)
1608–1615.
[32] C. Klein, T.Wuestefeld, U. Aßmus, M. Ernst, T. Roskams, S. Rose-John, M.Müller, M.
Manns, C. Trautwein, The interleukin-6/gp130/STAT3 pathway in hepatocytes
triggers liver protection in T-cell mediated liver injury, J. Clin. Invest. 115 (2005)
860–869.
[33] R. Sun, Z. Tian, S. Kulkarni, B. Gao, IL-6 prevents T cell-mediated hepatitis via
inhibition of NKT cells in CD4+ T cell- and STAT3-dependent manners, J.
Immunol. 172 (2004) 5648–5655.
[34] A. Mackiewicz, H. Schooltink, P.C. Heinrich, S. Rose-John, Complex of soluble
human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins, J.
Immunol. 149 (1992) 2021–2027.
[35] M. Peters, A.M. Müller, S. Rose-John, Interleukin-6 and soluble interleukin-6
receptor: direct stimulation of gp130 and hematopoiesis, Blood 92 (1998)
3495–3504.
[36] M. Peters, S. Jacobs, M. Ehlers, P. Vollmer, J. Müllberg, E. Wolf, G. Brem, K.H. Meyer
zum Büschenfelde, S. Rose-John, The function of the soluble interleukin 6 (IL-6)
receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice
301S. Malchow et al. / Biochimica et Biophysica Acta 1812 (2011) 290–301towards IL-6 and prolongation of the plasma half-life of IL-6, J. Exp. Med. 183
(1996) 1399–1406.
[37] K. Maezono, K. Mawatai, K. Kajiwara, A. Shinkai, T. Maki, Effect of alanine on D-
galactosamine-induced acute liver failure in rats, Hepatolgy 24 (1996) 1211–1216.
[38] F. Lafdil, H. Wang, O. Park, W. Zhang, Y. Moritoki, S. Yin, X.Y. Fu, M.E. Gershwin, Z.
X. Lian, B. Gao, Myeloid STAT3 inhibits T cell-mediated hepatitis by regulating Thelper 1 cytokine and interleukin-17 production, Gastroenterology 137 (2009)
2125–2135.
[39] F. Walker, H.H. Zhang, V. Matthews, J. Weinstock, E.C. Nice, M. Ernst, S. Rose-
John, A.W. Burgess, IL6/sIL6R complex contributes to emergency granulopoie-
tic responses in G-CSF- and GM-CSF-deﬁcient mice, Blood 111 (2008)
3978–3985.
